EFFECT OF HIGH-DOSE CYTARABINE TOSINE ARABINOSIDE THERAPY ON PATIENTS WITH ACUTE MYELOID LEUKEMIA
Objective To assess the efficacy of high-dose cytarabine (HD-Ara-C) and multi-drug alternating chemotherapy (MDAC) for intensive treatment of patients with acute myeloid leukemia (AML) after remission.Methods Clinical data of 57 patients with AML were analyzed retrospectively.According to the different intensive treatment plan,the patients were divided into HD-Ara-C group (n=27) and MDAC group (n =30).Patients in the two groups were all induced by IDA regimen to complete remission.Patients in the HD-Ara-C group received high-dose cytarabine therapy for four courses of treatment,and those in the MDAC group received multi-drug alternating chemotherapy-Daunorubicin+ standard dose cytarabine,huperzine A +standard dose cytarabine or mitoxantrone + standard dose cytarabine for four courses.Rates of adverse reactions,leukemia minimal residual disease (MRD),one-year and three-year overall survival as well as disease-free survival (DFS) were compared between the two groups.Results The difference in incidence of adverse reactions between the two groups was not significant (P>0.05).The MRD negative patients accounted for 81.5 % (22/27) in HD-AraC group versus that for 40.0% (12/30) in multi-drug group,the difference was significant (x 2 =10.159,P < 0.05).The one-year and three-year overall survival,as well as DFS in HD-AraC group were higher than that in the MDAC,the differences were significant (x2=4.657-9.156,P<0.05).Conclusion High-dose cytarabine intensive treatment can significantly reduce residual leukemic cells,increase one-year,three-year and overall survival,as well as disease free survival,which can be used as the preferred treatment for patients with acute myeloid leukemia after induction remission.